Document:

exv10w8

 

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

Exhibit 10.8

					
	 	 	 	 	 
	 
	 	PATENT LICENSE AGREEMENT
	 	3950.LICI.001 Gyros AB

This Agreement, effective as of January 9, 2003, is made by and between GYROS AB having its
principal office at Uppsala Science Park, SE-751 83 Uppsala, Sweden, a corporation organized and
existing under the laws of Sweden (hereinafter referred to as
“Licensor”), and FLUIDIGM Corporation
having its principal office at 7100 Shoreline Court, South San Francisco, CA 94080, a corporation
organized and existing under the laws of the state of California, U.S.A (hereinafter referred to as
the “Licensee”).

 

RECITALS

WHEREAS, the Licensor is the holder of intellectual property pertaining to, and possesses a special
expertise in the field of fluidic microsystems.

WHEREAS, the Licensor is active in the field of microfluidics and microfluidic applications,
primarily within the Life Sciences and Diagnostics.

WHEREAS, the Licensor is the owner of certain patents and patent applications pertaining to
microfluidics and microfluidic applications.

WHEREAS, Licensor is willing to grant Licensee a royalty-bearing non-exclusive licence to such
patents on the terms and conditions given below.

NOW, THEREFORE, in consideration of the promises and the faithful performance of the covenants
herein contained IT IS AGREED;

ARTICLE 1 DEFINITIONS

	1.1	 	“Affiliate” shall mean any corporation, partnership, or other business entity
controlled by, or controlling, or under common control with any party or signatory to this
Agreement, with “control” meaning direct or indirect beneficial ownership of more than fifty
percent (50%) of the voting power, or of the interest in the income of such corporation,
partnership or other entity, or having the power to appoint the majority of its directors or
otherwise having the power to direct its business activities.

1.2     “Competitor of Licensor” shall mean a company in the business of making and selling
compact disc-like structures in which fluids are moved by centrifugal force.

 

 

1.3 “Net Sales” shall mean the gross selling price charged by Licensee for Products
manufactured or sold by the Licensee in a country in which the Product is covered by a Patent
(i.e., a country in which, but for the license granted herein, the Product would infringe a valid,
enforceable, unexpired claim of a Patent) less:

	 	(a)	 	allowances for damaged and returned goods;
	 
	 	(b)	 	discounts actually credited to customers or commissions paid to third parties in amounts
customary in the trade;
	 
	 	(c)	 	custom duties, forwarding insurance premiums, sales, excise, and other taxes actually paid by
the Licensee or otherwise included in the gross selling price with respect to the sale of Products;

A Product shall be considered sold hereunder in accordance with extant GAAP accounting procedures
and guidelines.

If the Products are sold in combination with, or as a component of, other products not licensed
hereunder, Net Sales for purposes of determining royalty hereunder shall be calculated by
multiplying the Net Sales from the combined product by the fraction
A/B, where A is the invoice price of the Products sold separately and B is the invoice price of the
combined product. If the Products are not sold separately, the Net Sales for purposes of
calculating royalties hereunder shall be reasonably determined by agreement of Licensor and the
Licensee promptly after such combination products are sold by Licensee. The parties agree to use
good faith in negotiating the appropriate adjustment to Net Sales of any combined product within
thirty (30) days after the Licensee notifies Licensor of sales of a combination product. The Net
Sales of any Products sold by the Licensee to any Affiliate of the Licensee or any other person or
organization enjoying a special course of dealing with the Licensee, shall be determined by
reference to the Net Sales which would be applicable under this Article 1.2 in an arm’s length sale
of such Products by the Licensee to a third party.

1.4 “Patents” shall mean the patents listed in Exhibit A, attached hereto, together with
any other corresponding patents/ patent applications in any country owned or controlled by the
Licensor.

1.5 “Covered Products” shall mean all products now or hereafter manufactured, assembled, used
or sold by or on behalf of the Licensee or its Affiliates and which are covered by any of the
Patents.

It is hereby acknowledged that any and all products consisting of compact discs (“CD’s”) and
CD-like structures where a centrifugal force is utilized to move the liquids within the CD are
explicitly excluded from this definition.

	1.6	“Option Field of Use” means each of (i) [***] and (ii) [***].

 

 

	 	 	“Licensed Fields of Use” means [***] and each Option Field of Use for which
Licensee exercises the option as set forth in Section 5.2 below.
	 
	1.8	 	“Product” means each Covered Product useful, used, or for use in a Licensed Field of Use.

ARTICLE 2 GRANT

2.1 Upon the terms and subject to the conditions of this Agreement, Licensor hereby grants
to the Licensee and its Affiliates, and the Licensee and its Affiliates accept from Licensor, a
restricted, perpetual, irrevocable (except as set forth in
Section 9.1), non-exclusive,
non-transferable (except as set forth in Section 7.4), royalty-bearing license under the Patents
for the term hereof solely to make, have made, import, use, offer for sale, and sell Products. No
other license is granted to the Licensee expressly, impliedly or by estoppel, except as explicitly
set forth in Section 5.2 below.

	 	 	The Licensee expressly acknowledges and agrees that the Licensee shall have no right to sublicense,
assign, or otherwise transfer any or all of the license granted to it under the Patents, except as
set forth in Section 9.1, provided that Licensee can sublicense Patents to a third party other than
a Competitor of Licensor (as defined in Section 7.4) in conjunction with a license from Licensee to
make and sell any of Licensee’s Products. Licensor reserves the right to practice the Patents
itself, and to sublicense, assign or otherwise transfer the Patents to others for any purposes
whatsoever, provided that such transfer or assignment shall be subject to the licenses granted to
Licensee in this Agreement.
	 
	2.3	 	Licensor hereby irrevocably releases Licensee and its Affiliates, and each of their
subcontract manufactures and direct and indirect customers, of and from all claims of infringement
of Patents, known or unknown, which claims have been made or might have
been made at any time, with respect to any apparatus made, used, imported, offered for sale, or
sold, or any method or process practiced, before the effective date of this Agreement, which
apparatus, method, or process would have been licensed had it been made, used, imported, offered
for sale, or sold, or practiced after effective date of this Agreement. A corresponding release
will be deemed made in relation to each of the Option Fields of Use when and if exercised under
Section 5.2 below.

ARTICLE 3 PATENT MARKING

Beginning two (2) years after the effective date of this Agreement, Licensee shall display or cause
to be displayed proper patent notices on the documentation, inserts, packages or containers of all
Products which shall indicate that the Product is sold or manufactured under a patent license from
Licensor. The Licensee shall provide Licensor for its review prior to use,

 

 

representative samples containing such patent notices and the parties agree to use good faith in
determining the requirements for and adequacy of such notices under the controlling patent laws.

ARTICLE 4 RESTRICTIONS ON PUBLICATION

Upon the signing of this Agreement and upon exercise of any of the Option Fields of Use under 5.2,
both parties shall be entitled to make public — through a press
release or otherwise - that Licensee
has taken a license to the Patents from the Licensor. Such press-release or similar shall be in a
form reasonably acceptable to the other party and shall not disclose any of the financial terms
agreed in this Agreement. Within thirty (30) days of the effective date of this Agreement, Licensee
will publish on its corporate website that it has taken a license from Licensor under the Patents.
Under all other circumstances, neither party shall use the other’s name nor any variation thereof,
nor any emblem, logo, trademark or variation thereof, nor the name of any employee in any press
releases, advertising, promotional or sales literature, or in any securities reports required by
the Securities and Exchange Commission, without the prior written consent of the other party in
each case; provided however, that both parties (a) may refer to publications by employees of the
other party in the scientific literature, (b) may only state that a non-exclusive, royalty-bearing
patent license from Licensor to Licensee has been granted (excluding financial terms) and (c) may
make such disclosures as required by law.

ARTICLE 5 ROYALTIES AND PAYMENT

5.1 In consideration of the rights granted by Licensor to the Licensee under this Agreement, the
Licensee agrees to pay to Licensor:

	 	(a)	 	a non-refundable sum of [***] payable on March 31,
2003 (“Annual Payment Date”). The foregoing payment includes full payment for all sales by the
Licensee of Products before the effective date of this Agreement;
	 
	 	(b)	 	a sum of [***] payable on each anniversary of the
Annual Payment Date during the term of this Agreement; and
	 
	 	(c)	 	a royalty of [***] of the Net Sales of all Products sold by the Licensee during the
term of this Agreement. Sums paid under Subsections 5.1 (a) and (b) above, and Section 5.2 below,
shall be fully creditable against such royalties, regardless of the year in which such royalties
accrue.

5.2 At any time(s) during the first twelve (12) months of the term of this Agreement, Licensee
shall be entitled, at its option, to add one or both Option Fields of Use to the
Licensed Field of Use under this Agreement, and upon each such exercise, each such Option Field of
Use shall become a Licensed Field of Use under this Agreement. If Licensee has not, during the
first

 

 

twelve (12) month period of the term of this Agreement, added both Option Fields of Use to the
Licensed Field of Use, then during the second twelve (12) month period of the term of this
Agreement, Licensee shall be entitled, at its option, to add one Option Field of Use to the
Licensed Field of Use under this Agreement. Each such exercise of this option by Licensee shall be
by written notice to Licensor, referencing this Agreement and specifying the Option Field(s) of Use
to be added. Within thirty (30) days after such exercise, Licensee shall pay an additional
[***] license fee for the first added Option Field of Use, and an additional [***]
license fee for the second added Option Field of Use. For the avoidance of doubt, during the first
twelve (12) month period of the term of this Agreement, Licensee may exercise this option for one
or both Option Fields of Use and on one or two occasions.

5.3 Within thirty (30) days of the end of each calendar quarter the Licensee shall pay to Licensor
the royalty having accrued on the Products sold during such calendar quarter to the extent the
royalty exceeds the credited sums paid by Licensee. Such payments shall be made in US Dollars by
wire transfer, at the Licensee’s cost, to such bank as shall be notified by Licensor. Payments of
royalties accrued on sales in other currencies than US Dollars shall be made in US Dollars at the
rate of exchange quoted by a first class commercial bank in the Licensee’s country on the last day
of the relevant calendar quarter.

5.4 If the Licensee fails to make the payments as provided for herein, such amounts shall bear
interest from and after the due date at the rate of [***] above the one month LIBOR
for the currency of payment.

5.5 Withholding or other taxes assessed on Licensor in connection with the payment of royalties
and other consideration due hereunder and which the Licensee is required by law to deduct and
withhold when making payments, may be deducted from royalty payments hereunder (including without
limitation payments under Sections 5.1(a), 5.1(b), and 5.2) and shall be paid by the Licensee to
the competent authority on behalf of Licensor. The originals of the official government receipt for
such taxes paid by the Licensee on Licensor’s behalf, shall so indicate such fact and shall be sent
by the Licensee to Licensor not later than fifteen (15) working days after the date of payment,
indicating net payment of royalties to which such taxes relate, and in accordance with the
instructions given by Licensor. The sums so paid by the Licensee shall be credited by Licensor in
partial discharge of the Licensee’s obligation for gross royalties as provided for herein.

ARTICLE 6 RECORDS, AUDITS AND REPORTS

6.1 The Licensee agrees to maintain accurate, complete and up to date records, until five (5)
years after a royalty payment has been made, in sufficient detail to enable the royalties payable
by the Licensee to be determined. Licensor shall have the right, at its own expense and during
regular business hours, at any time upon sixty (60) days prior written notice to Licensee, during
the term of this Agreement and for one (1) year thereafter, to have such records examined, in its
own discretion, by an independent auditor of its own choice, provided such auditor is bound by
confidentiality in writing to Licensee and reasonably acceptable to the

 

 

Licensee. The auditor shall not disclose the contents of the examination to any other entity and
shall use the information only to verify proper reporting and payment of royalties under this
Agreement.

6.2 Once Licensee’s royalty obligations have exceeded the sums paid under Subsections 5.1(a) and
(b) above or in the event of a completed initial public offering of Licensee’s common stock, then
Licensee agrees to deliver to Licensor within forty-five (45) days of the end of each subsequent
calendar quarter a confidential written report, in a format to be agreed by the parties and made an
exhibit to this Agreement, of all Products sold by it during such quarter in sufficient detail to
permit a calculation of the royalties due thereon. Licensor shall not disclose the contents of the
report to any other entity and shall use the information only to verify proper reporting and
payment of royalties under this Agreement. Such report shall include, but not be limited to,
information of the total quantities of Products sold and the Net Sales thereof on a country by
country basis, and the amount of royalties due.

ARTICLE 7 TERM AND TERMINATION

7.1 Unless otherwise terminated as provided for in this Agreement, the license shall run to the
end of the life of the last to expire of the Patents.

7.2 The Licensee shall have the right to terminate this Agreement and surrender the license
granted hereunder at any time by giving thirty (30) days’ written notice to Licensor.

7.3 If Licensor or the Licensee is in default in the performance of any of its respective
obligations under this Agreement, including the failure by the Licensee to make any of the payments
provided for at the times specified herein, and such default is not cured within ninety (90) days
after the aggrieved party has given to the other a written notice specifying the nature of the
default, the aggrieved party shall have the right to terminate this Agreement by giving written
notice of termination to the other, subject to the remainder of this section. Upon the giving of
such notice this Agreement shall terminate; provided, however, that if there is a dispute as to the
alleged default (including as to whether there is a default, or whether it has been cured), the
aggrieved party alleging the default shall not be entitled to terminate unless and until a further
notice of termination after (i) an agreed dispute resolution entity has determined that there was a
default, as specified in the aggrieved party’s notice of default, that was not cured within the
applicable cure period and (ii) the defaulting party does not cure the default within thirty (30)
days after such determination.

7.4 If during the term of this Agreement, Licensee effects a Competitor Assignment (as defined in
Section 9.1), or a change of control over Licensee takes place meaning that fifty percent (50%) or
more of the shares in Licensee come under common control of a third party Competitor of Licensor or
Affiliates of such Competitor of Licensor, or if Licensee and/or certain of its shareholders enter
into an arrangement of a similar effect, Licensor shall be entitled to terminate this Agreement on
sixty (60) days prior written notice to Licensee. Upon such termination by Licensor, Licensor shall
promptly refund to Licensee (or its successor) a

 

 

pro rata (on a day for day basis) the annual payment made by Licensee for that year
under Section 5.1(a), 5.1(b), or 5.2, as applicable.

7.5 If during the term of this Agreement, the Licensee becomes bankrupt or insolvent, or if the
business of Licensor or the Licensee is placed in the hands of a receiver or trustee, whether by
voluntary act or otherwise, this Agreement shall immediately and automatically terminate.

7.6 The following rights and obligations shall survive any termination to the degree necessary to
permit their complete fulfilment or discharge:

	 	(a)	 	the Licensee’s obligation to supply a final report on each impacted Product in accordance
with Section 6.2 above with respect to the terminated license;
	 
	 	(b)	 	Licensor’s right to receive or recover and the Licensee’s obligation to pay royalties,
including minimum royalties, if any, accrued or accruable for payment at the time of any
termination;
	 
	 	(c)	 	the Licensee’s obligation to maintain records and to allow Licensor to audit such records
as provided for herein.

ARTICLE 8 RESTRICTED WARRANTY AND INDEMNITY

8.1 The Licensor represents and warrants that it has full authority to enter into this
Agreement, that it has not granted, and will not grant, any rights or licenses that would conflict
with the rights and licenses granted in this Agreement, that it is not aware of any third party
claims with respect to any Patent, and that it has no knowledge of any third party rights that
would affect its ability to grant the license hereunder. Licensor further represents and warrants
that the Patents are the only patent filings owned or controlled by Licensor or its Affiliates, or
which Licensor or its Affiliates otherwise have the right to enforce, license or sublicense, which
pertain to microfluidics based on multilayer soft lithography or its uses. However, the Licensor
makes no representation or warranty, express or implied, as to the validity of the Patents nor to
the merchantability or satisfactory quality of the Products that are or may be sold by the
Licensee. Licensor does not assume any liability for any infringement or alleged infringement of
any patent or other rights of third parties due to the Licensee’s activities under the license set
forth herein.

8.2 The Licensee shall assume full responsibility for its use of the Patents and shall defend
Licensor and its officers, directors, agents, and employees (“Indemnified Parties”) against any
claims or actions arising out of this Agreement by reason of death, personal injury, illness or
property damage, or any other injury or damage arising out of the use by the Licensee of the
Patents or the preparation of, use or sale of Products, including but not limited to, use or
reliance upon such Products by the Licensee’s customers, and Licensee shall indemnify the
Indemnified Parties against all liability, costs, damages, and expenses awarded against the
Indemnified Parties with respect to such claims or actions.

 

 

ARTICLE 9 MISCELLANEOUS

9.1 Assignment. This Agreement is personal to the Licensee who shall not have any right
to assign or transfer the Agreement, in whole or in part, or the license granted hereunder, without
the prior written consent of Licensor, which shall not be unreasonably withheld; provided, however,
that Licensee may transfer or assign its rights and obligations under this Agreement to a successor
to all or substantially all of Licensee’s Product business relating to one or more Licensed Fields
of Use, whether
by sale, merger or otherwise, provided further that that Licensee shall not have the right to
transfer or assign this Agreement to a Competitor of Licensor (“Competitor Assignment”) without the
prior written consent of Licensor . Notwithstanding the foregoing, Licensor shall have the right to
assign or transfer this Agreement, in whole or in part, to any Affiliate.

9.2 Entire Agreement. This Agreement constitutes the entire agreement between the
parties as to the subject matter hereof, and all prior negotiations, representations, agreements
and understandings are merged into, extinguished by and completely expressed by it. This Agreement
may be modified or amended only by a writing executed by authorized officers of each of the
parties.

9.3 Waiver. The waiver by either Licensor or the Licensee of any right or failure to
perform or of any breach by the other shall not be deemed as a waiver of any other right hereunder
or of any other breach or failure by the other, whether of a similar nature or otherwise.

9.4 Notices. Any notice or other communication relating to this Agreement shall be sent
registered mail or overnight express prepaid or telefax/telecopier to the address of the party to
be served therewith which is shown below and shall be deemed to have been given upon the date the
notice or communication was sent:

	 	 	 	 	 
	If to Licensor:

	 	Gyros AB
	 	Att: Maris Hartmanis
	 

	 	 	 	President & CEO
	 

	 	 	 	Uppsala Science Park
	 

	 	 	 	S-751 83 Uppsala, Sweden
	 
	 	 	 	 
	 

	 	 	 	          [***]
	 
	 	 	 	 
	with a copy to:

	 	rambe legal consultants
	 	Att: Lars J. Rambe, LL.M
	 
	 	 	 	 
	 

	 	 	 	Telefax +46-8-6508835
	 
	 	 	 	 
	If to the Licensee:

	 	Fluidigm Corporation	 	 

 

 

	 	 	 	 	 
	 

	 	 	 	Att: Gajus Worthington
	 

	 	 	 	President & CEO
	 

	 	 	 	7100 Shoreline Court
	 

	 	 	 	South San Francisco
	 

	 	 	 	CA 94080
	 
	 	 	 	 
	 

	 	 	 	Telefax: (650) 871-7152
	 
	 	 	 	 
	with a copy to:

	 	Fluidigm General Counsel
	 	Att: William M. Smith
	 
	 	 	 	 
	 

	 	 	 	Telefax: (650) 871-7195

Such addresses may be changed by notice so given.

9.5 Severability. If any provision of this Agreement is held to be unenforceable for any
reason, it shall be adjusted rather than voided, if possible, in order to achieve the intent of the
parties to the extent possible. In any event, all other provisions of this Agreement shall be
deemed valid and enforceable to the full extent possible consistent with the intent of the parties.

9.6 Governing Law. This Agreement and its effects shall be subject to and shall be
construed and enforced in accordance with the laws of the state of New York, U.S.A.

9.7 Disputes. Any dispute in connection with this Agreement shall be first elevated to
each party’s respective President for a period of thirty (30) days prior to giving a notice of
default under section 9.3 above, who shall convene a face-to-face meeting prior to pursuing any
legal courses of action.

IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized representatives
to execute this Agreement the day and year first above written.

	 	 	 	 	 	 	 	 	 	 	 
	Gyros AB	 	 	 	Fluidigm Corporation	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Maris Hartmanis
	 	 	 	By:
	 	/s/ Gajus Worthington	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Maris Hartmanis
	 	 	 	 	 	Gajus Worthington	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ (ILLEGIBLE)
	 	 	 	By:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 

 

 

Exhibit A

Patent family:

[***]exv10w8a

 

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

Exhibit 10.8A

AMENDMENT NO. 1 TO

PATENT LICENSE AGREEMENT

     This Amendment No. 1 (the “Amendment”) to the parties’ January 9, 2003 Patent License Agreement is
entered into as of the date of the latter signature below by and between GYROS AB having its
principal office at Uppsala Science Park, SE-751 83 Uppsala, Sweden, a corporation organized and
existing under the laws of Sweden (hereinafter referred to as
“Licensor”), and FLUIDIGM Corporation
having its principal office at 7100 Shoreline Court, South San Francisco, CA 94080, a corporation
organized and existing under the laws of the state of California, U.S.A (hereinafter referred to as
the “Licensee”).

RECITALS

     A. The parties have entered into a January 9, 2003 Patent License Agreement (the
“Agreement”); and

     B. The parties desire to amend the Agreement to include an additional Option Field of Use,
and to extend Licensee’s time period for exercising the remaining, unexercised Option Fields of
Use, on the terms and conditions set forth herein.

     NOW, THEREFORE, the parties agree that the Agreement is amended as follows:

     1. In order to add “protein analysis” as an additional Option Field of Use, Section 1.6 of the
Agreement is amended to read in its entirety as follows:

   “1.6 ‘Option Field of Use’ means each of (i) [***] (ii) [***] and (iii)
[***]”

It is acknowledged that Licensee has previously exercised its option in accordance with Section 5.2
of the Agreement for the Option Field of Use “nucleic acid analysis,” and made the required payment
with respect thereto, and that therefore “nucleic acid analysis” is already a Licensed Field of
Use.

     2. Section 5.1(b)
of the Agreement is amended by adding the following at the end: “, in
consideration of the rights granted to Licensee pursuant to Amendment No. 1 to this Agreement, on
or before February 9, 2005 Licensee shall pay to Licensee an additional, one time license fee of
[***] and”.

     3. With
respect to the remaining two Option Fields of Use (i.e. cell assays, and protein
analysis), Section 5.2 of the Agreement is amended to read in its entirety as follows:

“5.2
At any time(s) until and including January 9, 2007 (Pacific
Standard Time), Licensee shall be
entitled, at its option, to add one or both of the remaining, unexercised Option Fields of Use to
the Licensed Field of Use under this Agreement, and upon each such exercise, each such Option Field
of Use shall become a Licensed Field of Use under this Agreement. Each such exercise of this option

Page 1 of 2

 

by Licensee shall be by written notice to Licensor, referencing this Agreement and specifying the
Option Field(s) of Use to be added. Within thirty (30) days after each such exercise, Licensee
shall pay an additional [***] license fee for
each added Option Field of Use. For the avoidance of doubt, until and including January 9, 2007
(Pacific Standard Time), Licensee may exercise this option for one or both of the remaining,
unexercised Option Fields of Use and on one or two occasions.”

     4. All payments designated to be made in Swedish kronor shall be made by Licensee in Swedish
kronor by wire transfer to a Licensor account designated by Licensor, including all necessary
information, in writing to Licensee.

     5. Except as expressly provided in this Amendment, the Agreement shall remain unmodified and in
full force and effect. In the event of any inconsistency or conflict, the provisions of this
Amendment shall control and govern over the provisions of the Agreement. The Agreement, as amended
herein, shall constitute a single, integrated contract.

	 	 	 	 	 	 	 	 	 	 	 
	Gyros AB	 	 	 	Fluidigm Corporation	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Rolf Ehmstrom
	 	 	 	By:
	 	/s/ Gajus Worthington	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 
	Print Name: Rolf Ehmstrom	 	 	 	Print Name: Gajus Worthington	 	 
	 
	Title: CEO (acting)	 	 	 	Title: CEO	 	 
	 
	Date: 2005-01-09	 	 	 	Date: 01/04/05	 	 

Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]